2017整理急性冠脉综合征的抗凝抗血小板治疗-北京大学第三医院.pptVIP

ACS的发生机制 为什么需要抗凝抗血小板治疗？ 目前指南的抗凝抗血小板治疗推荐 需要关注的几个重要问题 四、特殊关注的几个问题(Issues-Special Focus) 出血是抗栓治疗的风险，出血增加病死率，增加费用 降低缺血事件和出血风险最低是临床的优先目标 风险积分可以评估院内出血风险 制定特殊的降低出血方案 适当的剂量 经桡动脉途径 轻度：CCr 60~90ml/min 中度：CCr 30~60ml/min 重度：CCr 30ml/min These data prompted the U.S. Food and Drug Administration to issue an advisory in February 2009 regarding the use of prasugrel in the abovementioned patient populations The 2007 ACC/AHA guidelines recommend that, for patients with UA/NSTEMI who will be treated initially according to an invasive strategy, either an intravenous GP IIb/IIIa inhibitor or clopidogrel should